Skip to main content

Table 1 Patients’ characteristics at baseline

From: Unincreased risk of hospitalized infection under targeted therapies versus methotrexate in elderly patients with rheumatoid arthritis: a retrospective cohort study

Variablea Young group (16–64 years old, n = 9122) Elderly group (65–74 years old, n = 7155) Older elderly group (over 75 years old, n = 6419)
Median age [IQR] 54 [45, 60] 70 [67, 72] 79 [77, 83]
Sex, female, % 75.3 69.6 72.9
Median observation period, months [IQR] 26 [13, 36] 24 [13, 36] 19 [10,34]
Median Charlson Comorbidity Index score [IQR] 1 [1, 2] 2 [1,3] 2 [1,3]
Comorbidity, %
 Chronic pulmonary disease 12.4 16.2 17.2
 Renal disease 1.8 3.5 4.9
 Diabetes mellitus 6.1 11.4 11.0
History of HI 2.8 4.1 6.1
Medication use for RA, %
 MTX 83.0 82.3 76.9
 bDMARDs 34.1 29.3 29.8
  TNF inhibitor 22.3 15.6 14.5
   Infliximab 4.0 1.6 0.6
   Etanercept 6.6 5.2 5.3
   Adalimumab 5.7 2.4 1.6
   Golimumab 4.3 5.5 6.6
   Certolizumab pegol 1.7 1.0 0.5
  Tocilizumab 7.9 5.7 4.4
  Abatacept 3.9 8.0 10.9
 JAKIs 1.3 1.7 1.5
  Tofacitinib 0.8 1.0 1.1
  Baricitinib 0.5 0.7 0.4
 Oral CS 43.5 47.8 55.5
 Median dose of oral CS, mg/day [IQR]b 5 [4, 10] 5 [4, 7.5] 5 [4, 7.5]
  1. bDMARDs Biological disease-modifying antirheumatic drugs, CS Corticosteroids, HI Hospitalized infection, IQR Interquartile range, JAKIs Janus kinase inhibitors, MTX Methotrexate, RA Rheumatoid arthritis, TNF Tumor necrosis factor
  2. aComorbidity and history of hospitalized infection were defined a year before the index month. Other variables were defined in the index month
  3. bDoses of oral corticosteroids were converted to prednisolone equivalent doses